Skip to content
10-Q

Quarterly Report

Inhibitor Therapeutics, Inc. INTI

0001493152-26-023622

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 15, 2026 172.57M sh
Shares Diluted Q1 2026 · Mar 31, 2026 172.57M sh
Shares Diluted Q1 2026 · Mar 31, 2025 172.32M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.08M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.28M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $1.29M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $2.38M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$1.98M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$1.29M
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.35M
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.99M
Current Liabilities Q1 2026 · Mar 31, 2026 $382.32K
Current Liabilities Q1 2026 · Dec 31, 2025 $766.33K
Total Liabilities Q1 2026 · Mar 31, 2026 $3.41M
Total Liabilities Q1 2026 · Dec 31, 2025 $3.8M
Current Assets Q1 2026 · Mar 31, 2026 $1.38M
Current Assets Q1 2026 · Dec 31, 2025 $2.45M
Total Assets Q1 2026 · Mar 31, 2026 $1.43M
Total Assets Q1 2026 · Dec 31, 2025 $2.51M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.00
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Eps Basic Q1 2026 · Mar 31, 2026 $0.00
Eps Basic Q1 2026 · Mar 31, 2025 $0.00
Sga Expense Q1 2026 · Mar 31, 2026 $355.07K
Sga Expense Q1 2026 · Mar 31, 2025 $438.49K
Rd Expense Q1 2026 · Mar 31, 2026 $340.56K
Rd Expense Q1 2026 · Mar 31, 2025 $236.06K
Net Income Q1 2026 · Mar 31, 2026 −$686.43K
Net Income Q1 2026 · Mar 31, 2025 −$632.85K
Operating Income Q1 2026 · Mar 31, 2026 −$695.63K
Operating Income Q1 2026 · Mar 31, 2025 −$674.55K